Puma Biotechnology Inc Stock Price, News & Analysis

Puma Biotechnology (NASDAQ: PBYI) presented findings at the 2020 SABCS, highlighting efficacy and safety for patients with CNS metastases from the NALA trial. The study showed that neratinib plus capecitabine (N+C) significantly improved progression-free survival (PFS) compared to lapatinib plus capecitabine (L+C), with a hazard ratio of 0.76. In the subgroup with CNS metastases, N+C demonstrated better PFS (7.8 months) versus L+C (5.5 months). The safety profile was consistent with overall results, with common adverse effects including diarrhea and nausea.

Puma Biotechnology (NASDAQ: PBYI) presented neratinib efficacy results for HER2-positive early-stage breast cancer from the Phase III ExteNET trial at the 2020 SABCS. The trial involved 2,840 patients, comparing neratinib (240 mg/day) to placebo after chemotherapy and trastuzumab. Key findings included 8-year overall survival (OS) rates of 90.1% for neratinib and 90.2% for placebo, with significant CNS metastasis reduction. Dr. Frankie Ann Holmes reported a notable OS improvement in high-risk patients not achieving a pathological complete response.

Puma Biotechnology, Inc. (Nasdaq: PBYI) presented updated results from the Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium. The trial evaluated neratinib in combination with trastuzumab and fulvestrant in patients with HER2-mutant, hormone receptor-positive metastatic breast cancer. Out of 37 evaluable patients, 45.9% achieved a confirmed objective response, with a median duration of response of 10.9 months. While the safety profile was consistent, 39.2% reported grade 3 diarrhea. The company continues patient enrollment for further study.

Puma Biotechnology, Inc. (NASDAQ: PBYI) has successfully upheld its European patent EP Patent 1848414, which pertains to irreversible EGFR inhibitors used in treating gefitinib and erlotinib-resistant cancers and T790M EGFR mutations. The European Board of Appeals announced the decision on December 1, 2023, rejecting an appeal from Boehringer Ingelheim. Originally granted in April 2011, the patent faced opposition in 2011, but the recent ruling reinstates the original claims without modification, solidifying Puma's intellectual property in this area.

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced the presentation of 10 abstracts at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from Dec 8-11, 2020. These abstracts cover the latest research on neratinib, particularly its effectiveness in treating HER2-positive breast cancer. Key presentations include findings from the SUMMIT trial, the ExteNET trial, and the NALA trial. Abstracts are publically accessible on the SABCS website, reflecting Puma's commitment to advancing cancer care through innovative therapies.

Puma Biotechnology announced on November 3, 2020, that its Board of Directors approved the grant of restricted stock unit awards covering 44,750 shares of common stock to five new non-executive employees. These awards, part of the 2017 Employment Inducement Incentive Award Plan, will vest over a three-year period. The first third vests on the anniversary of the award's commencement date, November 1, 2020, with subsequent vesting every six months. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology (NASDAQ: PBYI) announced interim results from the Phase II SUMMIT trial of neratinib for metastatic non-small cell lung cancer (NSCLC) patients with EGFR exon 18 mutations. Of the 10 evaluable patients previously treated with EGFR TKI, 60% achieved a partial response and 80% experienced clinical benefit. The median duration of response was 7.5 months, and median progression-free survival was 9.1 months. The study reported a manageable safety profile, with no grade 3 or higher diarrhea cases.

Puma Biotechnology (NASDAQ: PBYI) reported its Q3 2020 financial results, revealing a net loss of $31.5 million ($0.79 per share), compared to a loss of $16.9 million ($0.44 per share) in Q3 2019. Net revenue from NERLYNX decreased to $49.3 million from $53.5 million year-over-year. Total revenue for Q3 2020 was $50.8 million, down from $56.4 million in Q3 2019. Operating costs fell to $62.9 million from $70.8 million. As of September 30, 2020, cash and equivalents stood at $109 million. The company anticipates ongoing COVID-19 impacts but expects to release key trial data in the upcoming year.

Puma Biotechnology, Inc. (NASDAQ: PBYI) will have its CEO, Alan H. Auerbach, present at the Credit Suisse 29th Annual Healthcare Conference on November 10 at 1:15 p.m. EST. The event will be held virtually, and a live webcast can be accessed on Puma's website. The presentation will also be archived for 30 days post-event. Puma focuses on innovative cancer treatments, particularly through its FDA-approved product NERLYNX® (neratinib), used for specific breast cancer cases. More details can be found at www.pumabiotechnology.com.